Carlsmed, Inc. (NASDAQ:CARL) Given Average Recommendation of “Hold” by Analysts

Shares of Carlsmed, Inc. (NASDAQ:CARL) have earned a consensus rating of “Hold” from the five research firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $19.3333.

A number of research firms recently weighed in on CARL. The Goldman Sachs Group dropped their target price on Carlsmed from $19.00 to $17.00 and set a “buy” rating for the company in a research report on Thursday, April 9th. BTIG Research restated a “buy” rating and issued a $23.00 target price on shares of Carlsmed in a research report on Wednesday, May 6th. Zacks Research upgraded Carlsmed from a “strong sell” rating to a “hold” rating in a research report on Thursday, March 26th. Truist Financial dropped their target price on Carlsmed from $20.00 to $18.00 and set a “buy” rating for the company in a research report on Wednesday, April 15th. Finally, Wall Street Zen raised Carlsmed from a “sell” rating to a “hold” rating in a research note on Saturday, February 14th.

Hedge Funds Weigh In On Carlsmed

A number of large investors have recently bought and sold shares of CARL. BNP Paribas Financial Markets purchased a new position in Carlsmed in the 3rd quarter worth approximately $33,000. JPMorgan Chase & Co. purchased a new position in shares of Carlsmed during the third quarter valued at approximately $37,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of Carlsmed during the third quarter valued at approximately $42,000. Rhumbline Advisers purchased a new position in shares of Carlsmed during the third quarter valued at approximately $79,000. Finally, Wells Fargo & Company MN increased its stake in shares of Carlsmed by 61.7% during the fourth quarter. Wells Fargo & Company MN now owns 7,834 shares of the company’s stock valued at $97,000 after buying an additional 2,989 shares during the period.

Carlsmed Stock Performance

NASDAQ:CARL opened at $9.83 on Wednesday. The business has a 50 day moving average of $10.46 and a 200 day moving average of $12.07. The company has a market capitalization of $267.23 million and a price-to-earnings ratio of -3.92. Carlsmed has a 1-year low of $8.50 and a 1-year high of $17.19. The company has a debt-to-equity ratio of 0.17, a current ratio of 11.88 and a quick ratio of 11.67.

Carlsmed (NASDAQ:CARL) last released its earnings results on Tuesday, May 5th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.11. The company had revenue of $16.12 million during the quarter. Carlsmed had a negative return on equity of 60.74% and a negative net margin of 57.76%. On average, sell-side analysts predict that Carlsmed will post -1.35 earnings per share for the current fiscal year.

About Carlsmed

We are a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. We are focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of artificial intelligence (“AI”)-enabled software solutions, and interbody implants that we custom design for each patient’s unique pathology and vertebral bone topography, and single-use surgical instruments (the “aprevo Technology Platform”).